CD20-Targeted Therapy: The Next Generation of Antibodies

被引：63

作者：

van Meerten, Tom ^{[2
]}

Hagenbeek, Anton ^{[1
]}

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands

[2] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands

来源：

SEMINARS IN HEMATOLOGY | 2010年 / 47卷 / 02期

关键词：

ANTI-CD20; MONOCLONAL-ANTIBODY; CHRONIC LYMPHOCYTIC-LEUKEMIA; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; FC-GAMMA-RIIIA; FRESH-FROZEN PLASMA; FOLLICULAR LYMPHOMA; IN-VIVO; SIGNIFICANTLY IMPROVES; MAINTENANCE RITUXIMAB;

D O I：

10.1053/j.seminhematol.2010.01.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Targeting the CD20 antigen on B lymphocytes with the monoclonal antibody (MoAb) rituximab has greatly improved the outcome of patients with B-cell malignancies. Despite the success of rituximab, resistance occurs in about half of the patients, resulting in non-response to treatment or early relapse with the original disease. A better understanding of the mechanism of rituximab resistance has led to the development of novel, improved anti-CD20 antibodies. This review describes the development of CD20-targeted therapy from its historical background towards the next generation of anti-CD20 MoAbs and explains new strategies to overcome resistance. Semin Hematol 47:199-210. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：199 / 210

页数：12

共 114 条

[1]

ALDUAIJ W, 2009, ASH ANN M, V114, P725

[2] EXPRESSION OF HUMAN B CELL-ASSOCIATED ANTIGENS ON LEUKEMIAS AND LYMPHOMAS - A MODEL OF HUMAN B-CELL DIFFERENTIATION [J].

ANDERSON, KC ;

BATES, MP ;

SLAUGHENHOUPT, BL ;

PINKUS, GS ;

SCHLOSSMAN, SF ;

NADLER, LM .

BLOOD, 1984, 63 (06) :1424-1433

[3]

[Anonymous], ASH ANN M

[4] CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms [J].

Askew, D ;

Chu, RS ;

Krieg, AM ;

Harding, CV .

JOURNAL OF IMMUNOLOGY, 2000, 165 (12) :6889-6895

[5] Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance [J].

Bannerji, R ;

Kitada, S ;

Flinn, IW ;

Pearson, M ;

Young, D ;

Reed, JC ;

Byrd, JC .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1466-1471

[6] Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation [J].

Beers, Stephen A. ;

Chan, Claude H. T. ;

James, Sonya ;

French, Ruth R. ;

Attfield, Kathrine E. ;

Brennan, Claire M. ;

Ahuja, Anupama ;

Shlomchik, Mark J. ;

Cragg, Mark S. ;

Glennie, Martin J. .

BLOOD, 2008, 112 (10) :4170-4177

[7] Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species [J].

Bellosillo, B ;

Villamor, N ;

López-Guillermo, A ;

Marcé, S ;

Esteve, J ;

Campo, E ;

Colomer, D ;

Montserrat, E .

BLOOD, 2001, 98 (09) :2771-2777

[8] The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes [J].

Beum, PV ;

Kennedy, AD ;

Williams, ME ;

Lindorfer, MA ;

Taylor, RP .

JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2600-2609

[9] Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab [J].

Bowles, Julie A. ;

Wang, Siao-Yi ;

Link, Brian K. ;

Allan, Barrett ;

Beuerlein, Gregory ;

Campbell, Mary-Ann ;

Marquis, David ;

Ondek, Brian ;

Wooldridge, James E. ;

Smith, Brian J. ;

Breitmeyer, James B. ;

Weiner, George J. .

BLOOD, 2006, 108 (08) :2648-2654

[10] Pharmacokinetic and Pharmacodynamic Properties of TRU-015, a CD20-Directed Small Modular Immunopharmaceutical Protein Therapeutic, in Patients with Rheumatoid Arthritis: A Phase I, Open-Label, Dose-Escalation Clinical Study [J].

Burge, Daniel J. ;

Bookbinder, Stephen A. ;

Kivitz, Alan J. ;

Fleischmann, Roy M. ;

Shu, Cathye ;

Bannink, Jeannette .

CLINICAL THERAPEUTICS, 2008, 30 (10) :1806-1816

← 1 2 3 4 5 6 7 8 9 10 →